GlassScriptPhysician profile
Manjusha Kota
NPI 1629175922
$6,181.70
in general payments reported to CMS, 2019-2025
57 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $992 · 2021: $818 · 2022: $772 · 2023: $543 · 2024: $454 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,169.53 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $607.57 | 2019-2025 | |
| Pfizer INC. | $471.87 | 2019-2025 | |
| Amgen INC. | $278.37 | 2020-2022 | |
| Incyte Corporation | $264.12 | 2019-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $254.03 | 2019-2020 | |
| Eisai INC. | $230.36 | 2019-2021 | |
| Emd Serono, INC. | $166.64 | 2019-2025 | Bavencio |
| Janssen Biotech, INC. | $166.61 | 2019-2025 | Akeega, Erleada, Balversa |
| Foundation Medicine, INC. | $159.36 | 2019-2022 | |
| Glaxosmithkline, LLC. | $157.70 | 2023-2025 | Ojjaara |
| Genzyme Corporation | $155.53 | 2021-2025 | |
| Lilly USA, LLC | $150.33 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $148.31 | 2019-2025 | Imfinzi, Enhertu |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjusha Kota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.